Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Current Assets: 2010-2024

Historic Current Assets for Ligand Pharmaceuticals (LGND) over the last 15 years, with Dec 2024 value amounting to $331.6 million.

  • Ligand Pharmaceuticals' Current Assets rose 143.68% to $753.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $753.9 million, marking a year-over-year increase of 143.68%. This contributed to the annual value of $331.6 million for FY2024, which is 39.65% up from last year.
  • Ligand Pharmaceuticals' Current Assets amounted to $331.6 million in FY2024, which was up 39.65% from $237.4 million recorded in FY2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Current Assets peaked at $500.6 million during FY2020, and registered a low of $237.4 million during FY2023.
  • Over the past 3 years, Ligand Pharmaceuticals' median Current Assets value was $263.6 million (recorded in 2022), while the average stood at $277.5 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Current Assets crashed by 55.45% in 2020, and later spiked by 39.65% in 2024.
  • Ligand Pharmaceuticals' Current Assets (Yearly) stood at $500.6 million in 2020, then fell by 7.15% to $464.8 million in 2021, then plummeted by 43.28% to $263.6 million in 2022, then fell by 9.93% to $237.4 million in 2023, then soared by 39.65% to $331.6 million in 2024.